Ocugen Provides an Update on its COVAXI Pediatric (2-18) Emergency Use Authorization Request


MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) recently announced that the U.S. Food and Drug Administration (FDA), at this time, has declined to issue an EUA for COVAXIN™ for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.

Ocugen states that it intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN™.

Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

READ:  Harmony Biosciences' Narcolepsy Drug for Children Gets FDA Priority Review